Belgian biotech SME producing functional oligosaccharides and glycolipids for food, nutrition, and bio-based chemistry applications.
INBIOSE is a Belgian biotech SME specialising in carbohydrate chemistry and glycobiology — the science of complex sugars and their biological roles. Their core work involves designing and producing functional oligosaccharides and glycolipids, including biosurfactants and sialylated carbohydrates that mimic structures found in human milk and gut mucus. They apply fermentation and chemical biology methods to manufacture these compounds at scale, targeting applications in nutrition, health, and sustainable chemistry. Their location in Zwijnaarde, near Ghent, places them within one of Europe's strongest carbohydrate chemistry clusters.
CARBOSURF (2015–2018) directly targeted new fermentative processes for glycolipid biosurfactants and sialylated carbohydrates, reflecting INBIOSE's industrial production capability.
CARBOSURF included sialylated carbohydrate production, a compound class closely linked to infant nutrition and gut health applications.
SWEET CROSSTALK (2019–2023) trained glycoscientists in decoding glycocodes at the human gut interface, with INBIOSE contributing expertise in glycobiology and chemical biology.
SWEET CROSSTALK keywords — microbiota, microbiome, and mucin — indicate growing engagement with how glycan structures influence gut microbial ecology.
CARBOSURF was funded under BBI-RIA (Bio-Based Industries), signalling INBIOSE's contribution to the bio-economy and green chemistry agenda.
In their first H2020 project (2015–2018), INBIOSE focused squarely on production technology — fermentative manufacturing of glycolipids and sialylated carbohydrates with a bio-based industry framing. Their second project (2019–2023) shifted the lens toward fundamental science and training, exploring how glycan structures (glycocodes) interact with the gut microbiome and mucin layer. This suggests a maturing trajectory: from making complex sugars to understanding what they do inside the human body, which is typical of a company building both a product portfolio and scientific credibility simultaneously.
INBIOSE is moving up the value chain from production chemistry toward mechanistic understanding of glycan–microbiome interactions, positioning them as a future partner for functional food, prebiotics, and precision nutrition ventures.
INBIOSE has participated exclusively as a consortium partner across both projects and has never led as coordinator, suggesting they contribute specialist technical capacity rather than managing project consortia. With 23 unique partners across 9 countries from just 2 projects, they clearly engage in large, diverse research networks rather than tight repeat partnerships. This profile is typical of an SME that joins industry–academia consortia to access research infrastructure and validate technologies at a scale beyond their own resources.
INBIOSE has built a network of 23 unique partners across 9 countries through just two projects, an unusually broad reach for a small company, indicating active participation in large pan-European consortia. Their European footprint spans both industry and academia, consistent with BBI and MSCA programme structures.
INBIOSE occupies a rare niche as a private SME with deep carbohydrate chemistry capabilities — a field dominated by university research groups. Their combination of fermentation-based production know-how and glycobiology expertise makes them a credible industry partner for consortia that need someone who can translate molecular science into manufacturable compounds. For businesses in infant nutrition, prebiotics, or bio-based surfactants, INBIOSE offers direct access to functional oligosaccharide technology without going through a large corporate intermediary.
